BTAI
Closed
Bioxcel Therapeutics Inc
1.97
+0.16 (+8.84%)
Last Update: 01 Jul 2025 23:06:00
Yesterday: 1.81
Day's Range: 1.86 - 2.
Send
sign up or login to leave a comment!
When Written:
18.66
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing novel drugs for the treatment of neurological and immuno-oncological disorders. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics Inc's proprietary platform, BXCL501, is a sublingual thin film formulation of dexmedetomidine, a selective alpha-2A adrenergic receptor agonist that is being developed for the treatment of agitation in patients with schizophrenia and bipolar disorder. The company is also developing other drugs, including BXCL701, a small molecule immune-oncology agent that targets the DPP8/9 and FAP enzymes, and BXCL502, a sublingual thin film formulation of meloxicam, a non-steroidal anti-inflammatory drug that is being developed for the treatment of acute pain. The company is publicly traded on the NASDAQ under the ticker symbol BTAI.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








